Analysts expect Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) to report $-0.04 EPS on March, 12.They anticipate $0.02 EPS change or 33.33% from last quarter’s $-0.06 EPS. After having $0.07 EPS previously, Amphastar Pharmaceuticals, Inc.’s analysts see -157.14% EPS growth. The stock decreased 0.16% or $0.03 during the last trading session, reaching $19. About 19,798 shares traded. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 8.19% since February 16, 2017 and is uptrending. It has underperformed by 8.51% the S&P500.
Gulfport Energy Corporation engages in the acquisition, exploration, exploitation, and production of natural gas, natural gas liquids , and crude oil in the United States. The company has market cap of $1.64 billion. The Company’s principal properties are located in the Utica Shale primarily in Eastern Ohio, along the Louisiana Gulf Coast in the West Cote Blanche Bay, and Hackberry fields. It has a 38.93 P/E ratio. The firm also has interests in the Niobrara Formation of Northwestern Colorado; Bakken Formation; Alberta oil sands in Canada; and Phu Horm gas field in Thailand.
Since January 1, 0001, it had 0 insider buys, and 8 selling transactions for $2.05 million activity.
The stock increased 1.65% or $0.14 during the last trading session, reaching $8.95. About 942,002 shares traded. Gulfport Energy Corporation (GPOR) has declined 45.17% since February 16, 2017 and is downtrending. It has underperformed by 61.87% the S&P500.
Encompass Capital Advisors Llc holds 9% of its portfolio in Gulfport Energy Corporation for 3.86 million shares. Oslo Asset Management As owns 1.46 million shares or 8.65% of their US portfolio. Moreover, Firefly Value Partners Lp has 7.8% invested in the company for 5.37 million shares. The Texas-based Brenham Capital Management L.P. has invested 6.97% in the stock. Geosphere Capital Management, a New York-based fund reported 100,000 shares.
Ratings analysis reveals 83% of Gulfport Energy’s analysts are positive. Out of 6 Wall Street analysts rating Gulfport Energy, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $30.0 while the high is $36.0. The stock’s average target of $33.67 is 276.20% above today’s ($8.95) share price. GPOR was included in 6 notes of analysts from August 29, 2016. Tudor Pickering downgraded the stock to “Hold” rating in Monday, October 24 report. Barclays Capital maintained the shares of GPOR in report on Thursday, February 16 with “Overweight” rating. The stock of Gulfport Energy Corporation (NASDAQ:GPOR) earned “Buy” rating by Goldman Sachs on Tuesday, October 18. Mizuho initiated the stock with “Buy” rating in Thursday, October 6 report. The stock of Gulfport Energy Corporation (NASDAQ:GPOR) earned “Buy” rating by Guggenheim on Monday, December 19. The firm has “Buy” rating by Williams Capital Group given on Monday, August 29.
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $873.54 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The company's product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.